The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•1 July 2026•

1 min read

FDA Selects Eli Lilly, Regeneron for PreCheck Drug Manufacturing Pilot

Key Facts

1The FDA has selected 7 companies, including Eli Lilly and Regeneron, for its PreCheck pilot program providing early technical guidance for new drug manufacturing facilities.

As part of efforts to boost domestic drug manufacturing, the FDA has selected seven companies for its PreCheck pilot program, including Eli Lilly (LLY) and Regeneron (REGN). The program offers early technical guidance for new manufacturing facilities to streamline regulatory approvals, according to BioSpace reports.

Eli Lilly shares closed at $1,199.43 and Regeneron at $623.54 on June 30, per market data. The pilot follows a 2025 presidential order to promote U.S. drug production and could expedite facility approvals for selected companies, though the immediate financial impact is expected to be modest.

Sources: